FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1981870421> ?p ?o ?g. }

• W1981870421 endingPage "472" @default.
• W1981870421 startingPage "468" @default.
• W1981870421 abstract "Abstract Background In Japan, the eradication rate of first‐line therapy for Helicobacter pylori ( H. pylori ) with a proton pump inhibitor ( PPI ), amoxicillin ( AMPC ) and clarithromycin ( CAM ) has been decreasing because of a high prevalence of CAM resistance. A possible decrease of the eradication rate for second‐line therapy with a PPI , AMPC and metronidazole ( MNZ ) is of concern. The aim of this study is to assess the trends in second‐line eradication therapy for H. pylori in Japan. Materials and Methods We accumulated data retrospectively on patients administered second‐line eradication therapy for Helicobacter pylori with a PPI, AMPC, and MNZ for 1 week after failure of first‐line eradication therapy with a PPI, AMPC and CAM at 15 facilities in the Tokyo metropolitan area in Japan from 2007 to 2011. Trends for second‐line eradication rates in modified intention‐to‐treat ( ITT ) analyses were investigated. Second‐line eradication rates were categorized by three PPI s (rabeprazole ( RPZ ), lansoprazole ( LPZ ) or omeprazole ( OMZ )) and evaluated. Results We accumulated data on 1373 patients. The overall second‐line eradication rate was 92.4%. Second‐line eradication rates in 2007, 2008, 2009, 2010 and 2011 were 97.7, 90.6, 94.5, 91.8 and 91.8%, respectively, with no significant trends revealed. Second‐line eradication rates categorized by three PPI s for the entire 5‐year period were 91.6, 93.4 and 92.4% ( RPZ , LPZ and OPZ , respectively) with no significant differences among the three PPI s. Conclusions From 2007 to 2011, there were no significant trends in the second‐line eradication rates and the rates remained consistently high. From the viewpoint of high prevalence of CAM resistance in Japan, triple therapy with PPI , AMPC and MNZ may be a better strategy for first‐line therapy compared to triple therapy with PPI , AMPC and CAM ." @default.
• W1981870421 created "2016-06-24" @default.
• W1981870421 creator A5004765432 @default.
• W1981870421 creator A5021423808 @default.
• W1981870421 creator A5028421346 @default.
• W1981870421 creator A5044667078 @default.
• W1981870421 creator A5047427658 @default.
• W1981870421 creator A5049272530 @default.
• W1981870421 creator A5052268269 @default.
• W1981870421 creator A5053521836 @default.
• W1981870421 creator A5056908198 @default.
• W1981870421 creator A5057705404 @default.
• W1981870421 creator A5057947442 @default.
• W1981870421 creator A5059441963 @default.
• W1981870421 creator A5061054284 @default.
• W1981870421 creator A5067776411 @default.
• W1981870421 creator A5072611129 @default.
• W1981870421 creator A5074025359 @default.
• W1981870421 creator A5074381287 @default.
• W1981870421 creator A5074761937 @default.
• W1981870421 creator A5089871753 @default.
• W1981870421 date "2013-06-18" @default.
• W1981870421 modified "2023-10-06" @default.
• W1981870421 title "Trends of Second-Line Eradication Therapy for<i>Helicobacter pylori</i>in Japan: A Multicenter Study in the Tokyo Metropolitan Area" @default.
• W1981870421 cites W1513564170 @default.
• W1981870421 cites W1533868220 @default.
• W1981870421 cites W1895495328 @default.
• W1981870421 cites W1983119460 @default.
• W1981870421 cites W1985139875 @default.
• W1981870421 cites W1995346848 @default.
• W1981870421 cites W2025995260 @default.
• W1981870421 cites W2050132242 @default.
• W1981870421 cites W2051365849 @default.
• W1981870421 cites W2075697365 @default.
• W1981870421 cites W2080287054 @default.
• W1981870421 cites W2091925088 @default.
• W1981870421 cites W2092087978 @default.
• W1981870421 cites W2092372945 @default.
• W1981870421 cites W2094254472 @default.
• W1981870421 cites W2097521996 @default.
• W1981870421 cites W2100189346 @default.
• W1981870421 cites W2101730203 @default.
• W1981870421 cites W2132269037 @default.
• W1981870421 cites W2143131739 @default.
• W1981870421 cites W2155434182 @default.
• W1981870421 cites W2158819521 @default.
• W1981870421 doi "https://doi.org/10.1111/hel.12063" @default.
• W1981870421 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23773231" @default.
• W1981870421 hasPublicationYear "2013" @default.
• W1981870421 type Work @default.
• W1981870421 sameAs 1981870421 @default.
• W1981870421 citedByCount "20" @default.
• W1981870421 countsByYear W19818704212013 @default.
• W1981870421 countsByYear W19818704212014 @default.
• W1981870421 countsByYear W19818704212015 @default.
• W1981870421 countsByYear W19818704212016 @default.
• W1981870421 countsByYear W19818704212017 @default.
• W1981870421 countsByYear W19818704212018 @default.
• W1981870421 countsByYear W19818704212019 @default.
• W1981870421 countsByYear W19818704212020 @default.
• W1981870421 countsByYear W19818704212022 @default.
• W1981870421 countsByYear W19818704212023 @default.
• W1981870421 crossrefType "journal-article" @default.
• W1981870421 hasAuthorship W1981870421A5004765432 @default.
• W1981870421 hasAuthorship W1981870421A5021423808 @default.
• W1981870421 hasAuthorship W1981870421A5028421346 @default.
• W1981870421 hasAuthorship W1981870421A5044667078 @default.
• W1981870421 hasAuthorship W1981870421A5047427658 @default.
• W1981870421 hasAuthorship W1981870421A5049272530 @default.
• W1981870421 hasAuthorship W1981870421A5052268269 @default.
• W1981870421 hasAuthorship W1981870421A5053521836 @default.
• W1981870421 hasAuthorship W1981870421A5056908198 @default.
• W1981870421 hasAuthorship W1981870421A5057705404 @default.
• W1981870421 hasAuthorship W1981870421A5057947442 @default.
• W1981870421 hasAuthorship W1981870421A5059441963 @default.
• W1981870421 hasAuthorship W1981870421A5061054284 @default.
• W1981870421 hasAuthorship W1981870421A5067776411 @default.
• W1981870421 hasAuthorship W1981870421A5072611129 @default.
• W1981870421 hasAuthorship W1981870421A5074025359 @default.
• W1981870421 hasAuthorship W1981870421A5074381287 @default.
• W1981870421 hasAuthorship W1981870421A5074761937 @default.
• W1981870421 hasAuthorship W1981870421A5089871753 @default.
• W1981870421 hasConcept C126322002 @default.
• W1981870421 hasConcept C2776409635 @default.
• W1981870421 hasConcept C2776962512 @default.
• W1981870421 hasConcept C2777396551 @default.
• W1981870421 hasConcept C2777498785 @default.
• W1981870421 hasConcept C2778715759 @default.
• W1981870421 hasConcept C2779116819 @default.
• W1981870421 hasConcept C2779708577 @default.
• W1981870421 hasConcept C2781025758 @default.
• W1981870421 hasConcept C2993493390 @default.
• W1981870421 hasConcept C3019258254 @default.
• W1981870421 hasConcept C501593827 @default.
• W1981870421 hasConcept C71924100 @default.
• W1981870421 hasConcept C86803240 @default.
• W1981870421 hasConcept C89423630 @default.
• W1981870421 hasConcept C90924648 @default.

• next